Engflag

Cyklonova

Quick links to important sections

Cyklonova

Cyklonova_EN

Method of action: Antiallergic, Antifibrinolytic, Antihemorrhagics, Anti-Inflammatory, Hemostatic

Treatment option: Allergy, Anemia, Canker Sore, Gastrointestinal Bleeding, Hives, Leukemia, Allergic Drug Reaction, Menorrhagia, Purpura, Stomatitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cyklonova

Property Description
Active ingredient Tranexamic Acid (TXA)
Form Oral tablet and intravenous solution
Pharmacological class Antifibrinolytic agent / Antihemorrhagic
Common use Reducing excessive blood loss
Origin Synthetic derivative (of the amino acid lysine)

What is Cyklonova and its Pharmacological Class?

Cyklonova is a brand-name pharmaceutical preparation containing the active ingredient Tranexamic Acid (TXA). It is primarily classified as an antifibrinolytic agent, which places it within the broader group of antihemorrhagic medications used to control bleeding. The medication's classification is rooted in its highly selective pharmacological action.

Chemically, Tranexamic Acid is a pure synthetic derivative of the essential amino acid lysine. Its classification as an antifibrinolytic is recognized globally. The medication is commonly supplied by various manufacturers as both a prescription-only medicine (POM) and, in some markets, as a lower-dose Pharmacy Medicine (P).

What is the General Purpose of Tranexamic Acid?

The general purpose of the medication is to prevent the premature dissolution of blood clots, thereby helping to control or prevent instances of excessive blood loss or hemorrhage. Its core function is to stabilize fibrin clots that the body has already formed.

This antihemorrhagic effect is achieved through its selective action to inhibit fibrinolysis, which is the natural biological process where the body breaks down a clot. Tranexamic Acid is a highly potent reversible inhibitor of plasminogen activation, effectively supporting the body's natural clotting mechanisms when they are overwhelmed. This makes it clinically recognized for scenarios requiring efficient blood loss reduction.

In What Forms is Cyklonova Available?

Cyklonova is a single-ingredient product commonly available in two distinct dosage forms to accommodate various patient needs. The medication can be obtained as an oral dosage form, specifically a tablet, intended for ingestion and systemic delivery via the digestive tract. Additionally, it is available as a sterile intravenous solution for injection, which facilitates direct delivery into the bloodstream for situations requiring rapid systemic action.

Regulatory References

  1. WHO Essential Medicines List - Tranexamic Acid
  2. Tranexamic Acid Intravenous (IV) Dosage

What side effects are possible with Cyklonova?

Possible Side Effects and Safety Information

The safety profile for Tranexamic Acid (Cyklonova) is structured according to regulatory classifications that group adverse events by frequency and the body system affected. These classifications dictate the potential risks documented in official government labeling.

Documented Adverse Reactions

The most common adverse reactions reported in regulatory documents are generally related to the Gastrointestinal Disorders system and are typically categorized as Common (occurring in 1 to 10 out of 100 people). These include nausea, vomiting, and diarrhoea.

Less frequently, Uncommon reactions may involve the skin, such as allergic dermatitis or other localized skin reactions.

Serious Adverse Reactions and Safety Constraints

The label specifies rare, but serious, adverse reactions, primarily thromboembolic events (including deep vein thrombosis, pulmonary embolism, and cerebral thrombosis) and convulsions (seizures). These serious events define key safety restrictions.

Tranexamic Acid is contraindicated in individuals with active thromboembolic disease or a history of convulsions. It is also contraindicated in patients with severe renal impairment due to the risk of the active substance accumulating in the body.

Population and Administration Notes

Official safety notes require caution for use in patients with impaired renal function and individuals with pre-existing thrombotic risk factors. For the intravenous solution, hypotension (low blood pressure) is explicitly associated in the label with too rapid injection, demonstrating an administration-related safety pattern.

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented profile of Cyklonova (Tranexamic Acid) overdosage based on official regulatory labeling. This section is not a substitute for seeking medical attention in an emergency.

Domain Official Regulatory Statements
Documented Overdose Presentations Severe gastrointestinal symptoms (Nausea, Vomiting, Diarrhea), Convulsions (Seizures), Hypotension, and Visual impairment [Source 1.1, 3.1].
Physiological Systems Affected Central Nervous System (CNS), Cardiovascular system, Gastrointestinal system, and Vascular system (Thromboembolism risk) [Source 1.1, 1.7].
Dose-related or Exposure-related Factors The intravenous form has been associated with fatal adverse reactions when inadvertently administered via the neuraxial route (e.g., intrathecally), resulting in seizures and cardiac arrhythmias [Source 1.8].
Population-specific Overdose Notes There is an increased risk of toxicity and drug accumulation in patients with renal impairment, as the drug is cleared primarily by the kidneys [Source 1.7].
Emergency-response statements Discontinue use immediately if visual or ocular symptoms or seizures occur [Source 1.7, 3.3].
When immediate medical help is required Seek immediate medical attention for signs of severe hypersensitivity, which regulatory guidance groups with emergency actions [Source 1.7].

Overdose Classifications (High-Level)

Classification Official Regulatory Statements
Severity classification Overdosage may be associated with life-threatening outcomes, including severe neurological events and thromboembolic events (venous/arterial thrombosis) [Source 1.7].
Overdose-context constraints No specific antidote is known; management is officially limited to symptomatic and supportive treatment [Inferred from regulatory management descriptions].

Resulting Overdose Structure

The regulatory documents define the overdose profile by identifying specific acute threats, including convulsions and severe hypotension, alongside the significant risk of thromboembolism [Source 1.1]. Official guidance mandates that patients seek immediate medical attention when severe or life-threatening symptoms are present. Management procedures, as described in the official labeling, require symptomatic and supportive treatment and may involve EEG monitoring if seizures are suspected [Source 1.7].

Therapeutic Uses of Cyklonova

What Cyklonova Treats: Main Uses and Benefits

Cyklonova (Tranexamic Acid) is an antihemorrhagic medication commonly used to help with managing and reducing excessive blood loss across several distinct clinical domains by supporting the body's existing blood clots. The core therapeutic benefit supports the preservation of blood volume and the moderation of severe bleeding symptoms. The medication may be applied when appropriate for scenarios involving increased breakdown of blood clots.

The medication is relevant for easing symptoms across several categories of conditions, including heavy menstrual bleeding (HMB), and may be applied when appropriate for managing symptoms related to physical discomfort following childbirth or during major surgical procedures. It is also applied in addressing recurrent issues like severe epistaxis (nosebleeds) and certain syndromes such as Hereditary Angioedema.

In acute settings, it contributes to easing the overall symptom load by minimizing blood volume reduction. For chronic conditions, it helps improve day-to-day comfort by lessening symptomatic severity.

Quick Fact: Relief for Heavy Menstrual Bleeding

The medication may assist with maintaining functional stability during menstruation by contributing to easing the overall symptom load associated with high volume blood flow.

Eligibility and Restrictions for Use

This section outlines the official eligibility and exclusion criteria for Cyklonova (tranexamic acid) based on government regulatory information.

Contraindicated Populations and Conditions

Cyklonova is absolutely contraindicated in several high-risk groups to prevent serious complications:

  • Patients with active venous or arterial thrombosis (e.g., DVT, pulmonary embolism) or a history of such events.
  • Individuals with a history of convulsions (seizures).
  • Those with severe renal impairment, as the drug can accumulate to toxic levels.
  • Patients with subarachnoid hemorrhage (for injection/IV form) due to reported risks of cerebral complications.
  • Hypersensitivity to the active substance or any excipients.

Population-Specific Restrictions

Population Group Official Regulatory Status
Pregnancy Not recommended or should be used only if clearly needed, as the drug crosses the placenta.
Lactation/Breastfeeding Not recommended by some authorities due to the drug being excreted into human milk.
Renal Impairment Severe impairment is contraindicated; mild-to-moderate impairment requires a reduced dosage based on kidney function tests.
Age Groups Children from one year old are generally eligible, but data on efficacy and safety are limited. Postmenopausal women are not indicated for the oral form used for heavy menstrual bleeding.
Administration Route The injectable form is contraindicated for neuraxial administration (e.g., intrathecal, epidural injection) due to neurotoxicity risk.

What should I know about interactions with other medicines?

Cyklonova (tranexamic acid) is an antifibrinolytic medicine that must be used with caution, as it can interact with several other medicines and products, potentially increasing the risk of thromboembolic events (blood clots). Always inform your healthcare provider of all prescription, over-the-counter, and herbal supplements you are taking.

Major Interactions (Increased Clotting Risk)

Combinations with the following types of medicines should generally be avoided or monitored closely due to a significantly increased risk of blood clots:

  • Combined Hormonal Contraceptives: This includes birth control pills, patches, or vaginal rings containing both estrogen and progestin.
  • Other Antifibrinolytic Agents: Medicines such as aminocaproic acid, which work similarly to Cyklonova.
  • Prothrombotic Agents: Certain agents used to treat bleeding disorders, such as some coagulation factor complexes (e.g., anti-inhibitor coagulant complex).

Other Significant Interactions

  • Anticoagulants: If you are taking medicines that prevent blood clotting (e.g., warfarin), concurrent treatment must be strictly supervised by a specialist in coagulation, as Cyklonova works in opposition to their function.
  • Tretinoin: Concomitant use with this medicine (used for certain cancers) may also increase the risk of clotting or bleeding complications.

Table of Interaction Severity

Drug Type Potential Effect Recommendation
Hormonal Contraceptives Increased risk of thrombosis (blood clots). Avoid use
Anticoagulants (Warfarin, etc.) Opposing actions on blood clotting. Close medical supervision
Tretinoin Increased risk of thromboembolic events. Monitor closely

Mechanism of Action

Targeted Inhibition of Fibrinolysis

The mechanism of Tranexamic Acid (TXA) is defined by its highly specific action within the fibrinolytic system, the biological process responsible for dissolving blood clots . The compound acts as a competitive inhibitor, binding to the Lysine Binding Sites (LBSs) on the inactive molecule plasminogen. This molecular interaction blocks plasminogen from adhering to the clot's surface, thereby preventing its activation into the clot-dissolving enzyme, plasmin.

Protection of Clot Integrity

By suppressing the formation of plasmin, the entire molecular cascade that cleaves the fibrin meshwork is interrupted. This action directly leads to the preservation of the structural integrity of an existing clot, which is the resulting physiological consequence of the mechanism. The mechanism only stabilizes the clot; it does not promote new clot formation (coagulation), confining its activity strictly to the regulation of clot breakdown.

Scope and Constraints

The mechanism's action is functionally dependent on the presence of an existing fibrin clot and circulating plasminogen. While its main action is peripheral, high concentrations can, at times, show a minor, non-primary mechanistic interaction with GABA-A receptors in the Central Nervous System, representing a known constraint on its mechanistic scope.

Dosage and Administration Information

How Cyklonova is Used: Administration Guidelines

Cyklonova (Tranexamic Acid) is administered according to procedural protocols. The medication is available in two primary delivery methods: an oral tablet for ingestion and a sterile intravenous (IV) solution for direct systemic delivery.

Labeled Dosing and Administration Parameters

Feature Instructional Parameters
Route of Administration Oral and Intravenous (IV).
Standard Oral Dose 1300 mg (two 650 mg tablets) per administration for cyclic use.
Frequency and Timing Typically three times daily (TID). The oral tablet may be taken with or without food.
IV Administration Rate Injection or infusion must be slow, not to exceed 1 mL/minute (100 mg/minute).
Course Duration Use is limited to a maximum of 5 days during the menstrual cycle for cyclic use.
Special Handling The oral tablet must be swallowed whole and is not to be broken, chewed, or crushed.

Population-Specific Administration

A dosage reduction is utilized for both oral and IV administration in patients with renal impairment, with specific dose modifications based on serum creatinine levels. The IV solution is strictly for intravenous use and must not be mixed with certain incompatible substances, such as blood products or penicillin-containing solutions. These instructions define the standardized use of the medicine across diverse clinical contexts.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cyklonova

Evidence for Use in Heavy Menstrual Bleeding (HMB)

Research exploring Cyklonova (Tranexamic Acid) in patients with heavy menstrual bleeding was studied for its use in conditions associated with functional limitations. Studies primarily examined the reduction in measured blood loss volume and shifts in patient-reported outcomes describing perceived discomfort and daily functioning. Recent evidence continues to explore optimal dosing strategies and its patterns in specific groups, such as individuals taking anticoagulants, where concerns about potential risks historically limited its use.

Evidence for Use in Acute Hemorrhage and Trauma

Studies focused on acute episodes where symptoms become more noticeable, particularly in major trauma and severe postpartum hemorrhage (PPH). Large-scale international trials examined critical endpoints, including survival rates and the requirement for blood product transfusions. Research suggests the observed patterns were associated with the specific timing of administration, with the most consistent findings linked to use within the first three hours after the acute event.

Evidence in Surgical Settings and Research Gaps

Cyklonova was evaluated in numerous studies across various types of elective surgery, focusing on preventing excessive blood loss and reducing the need for transfusions. While findings are generally consistent in describing these patterns, evidence quality varies due to differences in research methods, particularly regarding the route (intravenous versus topical application) and concentration used. Data for certain groups, such as pediatric or older adult patients, remain less characterized, and research is ongoing to refine the optimal use and further define the long-term effects for all indications.

Key Studies & References

  1. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial

Frequently Asked Questions (FAQ)

Common questions about Cyklonova (FAQ)

Q: How long does it take for Cyklonova to start working?

The onset of action for pain relief is often reported to begin within 30 minutes, and for fever, a noticeable reduction may occur within an hour. However, individual responses can vary significantly.

For effective relief, the medication is often recommended to be taken at the first sign of pain, as directed by the product label or a healthcare provider.

Q: Can I take Cyklonova on an empty stomach?

Taking Cyklonova on an empty stomach is generally permitted, but this may increase the likelihood of stomach irritation. To help minimize the potential for stomach upset, it is often suggested to take Cyklonova with food or milk.

A healthcare professional can provide guidance on the most appropriate method for taking this medication, especially for individuals with known stomach sensitivity or those taking it regularly.

Q: What happens if I miss a dose of Cyklonova?

If a dose is missed, a common regulatory statement is to take the missed dose when remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

It is important not to take a double dose to make up for a missed dose, as exceeding the recommended dosage increases the risk of serious side effects, including kidney issues.

Specific instructions should always be obtained from a healthcare professional or the product label.

How should Cyklonova be stored and disposed of?

How to Store and Dispose of Cyklonova

The official labeling for Cyklonova (Tranexamic Acid) tablets specifies strict storage and disposal requirements to ensure product stability and safety.

Storage Requirements

  • Temperature: The medicine must be stored at a temperature not above 30 C (86 F).
  • Protection: Cyklonova must be kept in the original container (blister pack) to protect it from light and moisture.
  • Child Safety: Store the product out of the sight and reach of children.

Disposal Instructions

  • Unused Product: There are no special handling requirements for the unused tablets.
  • Waste Protocol: Do not dispose of this medicine via wastewater or household waste. Unused or expired medication must be taken to a pharmacy or local collection point for safe disposal in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagDenmark

flagSweden

Equivalent of Cyklonova found in:

A-Z Index: